Factor V Leiden: Impact on infusion nursing practice

Journal of Infusion Nursing

Volumn 32, Issue 4, 2009, Pages 219-223

  Weinstein, Sharon M ^a  

^a Core Consulting Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; ENOXAPARIN; BLOOD CLOTTING FACTOR 5;

ANGIOGENESIS; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFUSION SYSTEM; LUNG EMBOLISM; NURSING PRACTICE; PREGNANCY DISORDER; PRIORITY JOURNAL; REVIEW; THROMBOPHILIA; VEIN THROMBOSIS; FEMALE; GENETIC PREDISPOSITION; GENETICS; NURSING; PREGNANCY; PREGNANCY COMPLICATION; RISK FACTOR;

FACTOR V; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; RISK FACTORS; VENOUS THROMBOSIS;

EID: 70349577655     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/NAN.0b013e3181aabdb1     Document Type: Review

References (16)

1. National Institutes of Health. Factor V Leiden thrombophilia. http://ghr.nlm.nih.gov/condition=factorvleidenthrombophilia/. Accessed February 24, 2009.
2. FVL Thrombophelia Support page. Factor V Leiden. http://www.fvleiden.org. Accessed May 10, 2006.
3. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J. 2006;4:15. http://www.thrombosisjournal.com/content/4/1/15. Accessed February 24, 2009.
4. Ehrenforth S, Nemes L, Mannhalter C, et al. Impact of environmental and hereditary factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V: G169'A. J Thromb Haemost. 2004;2:430-436. http://www.ncbi.nlm.nih.gov/pubmed/15009459?dopt. Accessed March 1, 2007.
5. Crookston KP, Henderson R, Chandler WL. False negative factor V Leiden assay following allogeneic stem cell transplant. Br J Haematol. 1998;100(3):600-602. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part= factor-v-leiden. Accessed February 17, 2007
6. Bauersachs RM. New anticoagulants. Hamostaseologie. 2008; 28(1-2):21-26.
7. Klinikum der Johann Wolfgang Goethe-Universität Frankfurt on Main. Annual report 2004. http://www.med.uni-frankfurt.de/Forschung/Jahresbericht/ Jahresbericht2004/JB2004.pdf. Accessed February 24, 2009.
8. National Cancer Institute. Angiogenesis. http://www.cancer.gov/ cancertopics/UnderstandingCancer/angiogenesis. Accessed November 1, 2008.
9. Ofri D. Evidence-based case review: diagnosis and treatment of deep vein thrombosis. West J Med. 2000;173(3):194-197.
10. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous lowmolecular-weight heparin administered at home: the Tasman Study Group [erratum in: N Engl J Med. 1997;337:1251].
11. N Engl J Med. 1996;334:682-687.
12. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Lowmolecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a cost-effective analysis. Ann Intern Med. 1999;130:789-799.
13. Cohn D, Vansenne F, DeBorgie C, Middeldorp S. Thombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev. 2009;(11): CD007069. doi:10, 1002/14651858. CD007069.pub2. http://mrw. interscience.wiley.com/cochrane/clsysrev/articles/CD007069/frame.html. Accessed May 1, 2009.
14. Nagy S, Lumby J. Nurses' beliefs about the conditions that hinder or support evidence based nursing. Int J Nurs Pract. 2001; 7(5):314-321.
15. Mountain States Genetics Foundation. Molecular genetic testing in mainstream medicine. Venous thrombosis and the factor V (Leiden) mutation. http://mostgene.org/gd/gdvol14b.htm. Accessed February 24, 2009.
16. Weinstein S. Certification and credentialing to define competencybased practice. J Intraven Nurs. 2000;23(1):21-28.